Press release
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2022
Revenue of $1.12 billion for Q3 2022, up 1% from Q3 2021, and up 3% on a constant currency basisGAAP diluted loss per share of $(24.26) for Q3 2022, compared
About this update from Illumina, Inc.
[{"type":"text","content":"Revenue of $1.12 billion for Q3 2022, up 1% from Q3 2021, and up 3% on a constant currency basisGAAP diluted loss per share of $(24.26) for Q3 2022, compared to GAAP diluted earnings per share of $2.08 for Q3 2021; GAAP diluted loss per share for Q3 2022 includes goodwill impairment of $3.91 billion related to the GRAIL segmentNon-GAAP diluted earnings per share of $0.34 for Q3 2022, compared to non-GAAP diluted earnings per share of $1.45 for Q3 2021Expect full year revenue for fiscal year 2022 to be flat to 1% higher compared to fiscal year 2021, primarily reflecting year-to-date growth in sequencing consumables revenue, largely offset by a fourth quarter decline in select research project sample volume; delayed purchases ahead of the upcoming availability of NovaSeq X and from customer inventory and capital management; and incremental foreign exchange headwindsExpect GAAP diluted loss per share of $(26.56) to $(26.41) for fiscal year 2022, which includes goodwill impairment of $3.91 billion related to the GRAIL segmentExpect non-GAAP diluted earnings per share of $2.35 to $2.50 for fiscal year 2022SAN DIEGO, Nov. 3, 2022 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) today announced its financial results for the third quarter of fiscal year 2022, which include consolidated financial results for GRAIL.\n\"Our third-quarter results were in line with our expectations, with traction across our portfolio offset by challenging macroeconomic dynamics that we expect will continue into 2023,\" said Francis deSouza, Chief Executive Officer. \"Customer response to our latest innovations has been very positive; we already have 50 NovaSeq X orders globally. As we close out 2022 and look toward 2023, we are focused on helping customers navigate the current environment and delivering these technologies to help customers reimagine what's possible with genomics.\"\nThird quarter consolidated results\nGAAP\nNon-GAAP (a)\nDollars in millions, except per share amounts\nQ3 2022 (b)\nQ3 2021\nQ3 2022 (b)\nQ3 2021\nRevenue\n$ 1,115\n$ 1,108\nGross margin\n64.3 %\n69.5 %\n68.4 %\n71.2 %\nResearch and development (\"R&D\") expense\n$ 325\n$ 436\n$ 324\n$ 240\nSelling, general and administrative (\"SG&A\") expense\n$ 146\n$ 879\n$ 336\n$ 288\nLegal contingency and settlement\n$ (11)\n$ —\n$ —\n$ —\nGoodwill impairment (c)\n$ 3,914\n$ —\n$ —\n$ —\nOpera...